Non-interaction Study of Chlorthalidone and Losartan in Fixed Combination, in Healthy Subjects, Under Fasting Conditions
NCT ID: NCT05090449
Last Updated: 2021-10-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
36 participants
INTERVENTIONAL
2019-05-01
2020-05-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A1: Individual formulation of chlorthalidone
(Higroton 50, product of Sandoz, S.A. de C.V.)
Chlorthalidone (HIGROTON® 50)
Tablets with 50mg of Chlorthalidone, product de Sandoz, S.A. de C.V.
A2:Individual formulation Losartan
(COZAAR, product of Schering Plough, S.A. de C.V., S.A. de C.V.)
Losartan (COZZAR®)
Losartan potassium 100 mg tablet, a product of Schering-Plough, S.A. C.V.
A3: Co-administration of individual formulations
Co-administration of individual formulations of chlorthalidone and losartan potassium
A1+ A2 Co-administration of Chlorthalidone and Losartan
50mg chlorthalidone + 100 mg losartan potassium
B: Fixed combination of chlorthalidone and losartan potassium
B: Fixed combination of chlorthalidone and losartan potassium (product of Laboratorios Silanes S.A. de C.V.)
Chlorthalidone + Losartan Fixed-Dose combination
Tablets with fixed combination of Chlorthalidone 25 mg and Losartan Potassium
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Chlorthalidone (HIGROTON® 50)
Tablets with 50mg of Chlorthalidone, product de Sandoz, S.A. de C.V.
Losartan (COZZAR®)
Losartan potassium 100 mg tablet, a product of Schering-Plough, S.A. C.V.
A1+ A2 Co-administration of Chlorthalidone and Losartan
50mg chlorthalidone + 100 mg losartan potassium
Chlorthalidone + Losartan Fixed-Dose combination
Tablets with fixed combination of Chlorthalidone 25 mg and Losartan Potassium
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Only healthy male volunteers between 18 and 55 years of age were included. - The body mass index of the subjects should be between 18.0-27.0 kg / m2 according to Quetelet.
* The volunteers must be healthy, a criterion determined by the results of a complete medical history carried out by the doctors of the Clinical Research site and the laboratory and clinical test (12-lead electrocardiogram) carried out by a certified Clinical Laboratory and / or staff of the Center.
* The limits of variation allowed within normality in the screening visit was: blood pressure (sitting) from 90 to 129 mm Hg systolic and 60 to 79 mm Hg diastolic, heart rate between 50 and 100 beats per minute and respiratory rate between 14 and 20 breaths per minute according to current SOP with code CLI-DES-008 "Measurement of Vital Signs". Vital signs will be taken after 5 minutes of resting in a sitting position.
* Subjects willing to practice abstinence as a lifestyle or use of two family planning methods (including barrier methods, non-hormonal intrauterine device or bilateral tubal obstruction, and hysterectomy) during the course of the clinical study and up to 30 days after the last dose.
* The laboratory and test examinations that will be carried out for the inclusion of the subjects during the selection visit to the study will be:
1. Complete hematic biometry with differential count: leukocytes, erythrocytes, hemoglobin, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, distribution width of erythrocytes, platelets, neutrophils, lymphocytes, monocytes, eosinophils, basophils.
2. 27-element blood chemistry: glucose, urea, BUN, creatinine, BUN / creatinine ratio, uric acid, cholesterol, HDL cholesterol, triglyperides, LDL cholesterol, Non-HDL cholesterol, atherogenic index, total proteins, albumin, globulins, A / ratio G, total bilirubin, direct bilirubin, indirect bilirubin, ALT (alanine aminotransferase), AST (aspartate aminotransferase), alkaline phostatase, gamma-glutamyltraspeptidase, LDH, iron, calcium, sodium, potassium, and chlorine.
3. General urine test. Physical examination (color, appearance, density); chemical examination (pH, leukocytes, nitrites, proteins, glucose, ketones, bilirubin, urobilinogen, hemoglobin); microscopic examination (leukocytes, erythrocytes, dysmorphic erythrocytes, casts, crystals, pavement cells, renal tubular cells, mucoid networks, bacteria, yeast).
4. Hepatitis B and C serum tests: HBV surface antigen and anti-HCV Antibody.
5. HIV serum tests: Anti-HIV \[Human immunodeficiency virus\] 1 and 2 antibodies.
6. VDRL \[Venereal Disease Research Laboratory\] serum test.
7. Urine drug abuse tests (qualitative) at screening visit and approximately 12 hours prior to each drug administration.
8. Inline alcohol detection test approximately 12 hours before each drug administration.
9. 12-lead electrocardiogram, which will be taken after 5 minutes of rest in the upright position.
Exclusion Criteria
* Volunteers requiring any medication during the course of the study, other than the medication being studied. - Volunteers with a history of dyspepsia, gastritis, esophagitis, duodenal or gastric ulcer. - Volunteers who have been exposed to drugs known as liver enzyme inducers or inhibitors or who have taken potentially toxic drugs within the 30 days prior to the start of the study.
* Volunteers who have received any medication, including vitamins (with or without a prescription) or herbal remedies 30 days (or 7 half-lives) prior to the start of the study. - Clinically significant abnormalities in the electrocardiographic trace. - Electrolyte disturbances: hypokalemia, hyponatremia, hypercalcemia, and symptomatic hyperuricemia.
* Volunteers who have been hospitalized for any problem during the six months prior to the start of the study.
* Subjects who received investigational drugs within 90 days (3 months) prior to the study. - Subjects allergic to study drugs: chlorthalidone and sulphonamide derivatives, as well as losartan.
* Subjects who have ingested alcohol and / or carbonated beverages and / or containing xanthines (coffee, tea, cocoa, chocolate, mate, cola soft drinks) or who have ingested charcoal-grilled food or grapefruit juice within the previous 10 hours at the beginning of each hospitalization period or subjects who smoked tobacco within 10 hours prior to the start of the study.
* Subjects who have donated or lost 450 mL or more of blood within the 60 days prior to the start of the study.
* Subjects with a history of drug abuse and / or alcoholism.
* Volunteers who require a special diet for any reason or are on a different diet, for example vegetarian.
* Incapacity of any kind that makes it impossible for the volunteer to understand the nature, objective and possible consequences of the study.
* Evidence of non-cooperative attitude during the development of the study.
* Volunteers with positive urine drug abuse test or breath alcohol test.
* Volunteers who are not registered on the COFEPRIS page.
* Relationship of subordination between research subjects and researchers.
* Employees of the Sponsor and / or IFaB.
18 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Laboratorios Silanes S.A. de C.V.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Araceli G Medina Nolasco, M.D
Role: PRINCIPAL_INVESTIGATOR
Investigación Farmacológica y Biofarmacéutica, S.A.P.I. de C.V.
Liz J Medina Reyes, M.D
Role: PRINCIPAL_INVESTIGATOR
Investigación Farmacológica y Biofarmacéutica, S.A.P.I. de C.V.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Laboratorio Silanes, S.A. de C.V.
Mexico City, , Mexico
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Bienert A, Brzeziniski R, Szalek E, Dubai V, Grzeskowiak E, Dyderski S, Drobnik L, Wolc A, Olejniczak-Rabinek M. Bioequivalence study of two losartan formulations administered orally in healthy male volunteers. Arzneimittelforschung. 2006;56(11):723-8. doi: 10.1055/s-0031-1296781.
Das AK, Dhanure S, Savalia AK, Nayak SK, Tripathy SK. Human bioequivalence evaluation of two losartan potassium tablets under fasting conditions. Indian J Pharm Sci. 2015 Mar-Apr;77(2):190-5. doi: 10.4103/0250-474x.156583.
del Castillo D, Campistol JM, Guirado L, Capdevilla L, Martinez JG, Pereira P, Bravo J, Perez R. Efficacy and safety of losartan in the treatment of hypertension in renal transplant recipients. Kidney Int Suppl. 1998 Dec;68:S135-9. doi: 10.1046/j.1523-1755.1998.06827.x.
Dudkowski C, Karim A, Munsaka M. Effects of Food Intake on the Pharmacokinetics of Azilsartan Medoxomil and Chlorthalidone Alone and in Fixed-Dose Combination in Healthy Adults. Clin Pharmacol Drug Dev. 2016 Sep;5(5):393-8. doi: 10.1002/cpdd.249. Epub 2016 Mar 4.
Mann R, Mackay F, Pearce G, Freemantle S, Wilton L. Losartan: a study of pharmacovigilance data on 14,522 patients. J Hum Hypertens. 1999 Aug;13(8):551-7. doi: 10.1038/sj.jhh.1000880.
Pentikis HS, Henderson JD, Tran NL, Ludden TM. Bioequivalence: individual and population compartmental modeling compared to the noncompartmental approach. Pharm Res. 1996 Jul;13(7):1116-21. doi: 10.1023/a:1016083429903.
Potvin D, DiLiberti CE, Hauck WW, Parr AF, Schuirmann DJ, Smith RA. Sequential design approaches for bioequivalence studies with crossover designs. Pharm Stat. 2008 Oct-Dec;7(4):245-62. doi: 10.1002/pst.294.
Shah JV, Patel DP, Shah PA, Sanyal M, Shrivastav PS. Simultaneous quantification of atenolol and chlorthalidone in human plasma by ultra-performance liquid chromatography-tandem mass spectrometry. Biomed Chromatogr. 2016 Feb;30(2):208-16. doi: 10.1002/bmc.3537. Epub 2015 Jul 7.
Zandbergen AA, Baggen MG, Lamberts SW, Bootsma AH, de Zeeuw D, Ouwendijk RJ. Effect of losartan on microalbuminuria in normotensive patients with type 2 diabetes mellitus. A randomized clinical trial. Ann Intern Med. 2003 Jul 15;139(2):90-6. doi: 10.7326/0003-4819-139-2-200307150-00008.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CLRLSR-32-SIL
Identifier Type: -
Identifier Source: org_study_id